otud6b Antibody

What is OTUD6B and why is it important in research?

OTUD6B (OTU domain-containing protein 6B) functions as a deubiquitinating enzyme that specifically targets ubiquitin chains on substrate proteins for removal, regulating protein stability and activity. This enzyme plays multiple critical roles in cellular function, making it an important research target.

Based on current evidence, OTUD6B exhibits several significant functions:

• Regulates protein synthesis downstream of mTORC1

• May associate with protein synthesis initiation complex and modify its ubiquitination

• Plays a role in proteasome assembly and function

• Significantly impacts cell growth and proliferation regulation

• Functions as a positive regulator of innate antiviral immunity by stabilizing IRF3 (Interferon Regulatory Factor 3)

Notably, recent research has uncovered OTUD6B's previously unknown role in enhancing type I interferon antiviral immune responses. Human OTUD6B stabilizes IRF3 protein by hydrolyzing K33-linked polyubiquitin at Lys315, preventing IRF3 degradation and enhancing the host's antiviral defense capability .

What experimental applications are OTUD6B antibodies validated for?

OTUD6B antibodies have been validated for several key experimental applications, though specific capabilities may vary between antibody clones and manufacturers. Research-based applications include:

When selecting an OTUD6B antibody, researchers should consider:

• The target epitope region (some antibodies target full-length protein while others recognize specific fragments)

• The molecular weight of the detected protein (approximately 34 kDa)

• Species cross-reactivity (most validated only for human samples)

• Whether the experiments will examine endogenous or overexpressed OTUD6B

How can I validate the specificity of OTUD6B antibodies before experimental use?

Validating antibody specificity is crucial for ensuring reliable experimental results. For OTUD6B antibodies, consider implementing these methodological approaches:

• Positive and negative control samples:

  • Use cell lines with known OTUD6B expression levels

  • Include OTUD6B knockdown samples using siRNA (as demonstrated in research where OTUD6B was downregulated by transfection of specific siRNA in 293T cells)

  • Compare with OTUD6B overexpression samples (exogenous expression of HA-tagged OTUD6B)

• Molecular weight verification:

  • Confirm detection at the expected molecular weight (approximately 34 kDa)

  • Account for post-translational modifications that might affect band migration

• Cross-validation approaches:

  • Use multiple antibodies targeting different epitopes of OTUD6B

  • Employ genetic approaches (CRISPR knockout) alongside antibody detection

  • Consider peptide competition assays to confirm specificity

• Isoform consideration:

  • Determine which isoforms your antibody detects (isoforms 1 and 2 have distinct functions)

  • Verify expression patterns in your experimental system match known distribution

What are the recommended protocols for OTUD6B detection by Western blotting?

For optimal detection of OTUD6B by Western blotting, consider the following methodological approach:

• Sample preparation:

  • Extract proteins using standard lysis buffers containing protease inhibitors

  • Include deubiquitinase inhibitors (N-ethylmaleimide) to preserve ubiquitination states if studying OTUD6B substrates

  • For viral infection studies, collect samples at specific time points (research shows OTUD6B protein levels increase and peak at 8 hours post-infection)

• Gel electrophoresis and transfer:

  • Load 20-40 μg of total protein per lane

  • Use 10-12% SDS-PAGE gels for optimal resolution around 34 kDa

  • Transfer to PVDF or nitrocellulose membranes (PVDF recommended for lower background)

• Antibody incubation:

  • Block membranes with 5% non-fat milk or BSA in TBST

  • Incubate with primary OTUD6B antibody at 1:1000 dilution overnight at 4°C

  • Wash thoroughly (3-5 times with TBST)

  • Incubate with appropriate HRP-conjugated secondary antibody

• Visualization and analysis:

  • Develop using ECL substrate and image

  • Expect a band at approximately 34 kDa

  • Consider stripping and reprobing for loading controls (β-actin, GAPDH)

  • For endogenous detection, some cell lines may require longer exposure times

How can I optimize experiments to study OTUD6B's role in antiviral immune responses?

To effectively investigate OTUD6B's role in antiviral immunity, consider these methodological approaches:

• Viral infection models:

  • Multiple RNA viruses have been validated for OTUD6B studies, including VSV, H1N1, SeV, RSV, and the DNA virus HSV-1

  • Time-course experiments are essential as OTUD6B protein levels increase and peak at 8 hours post-infection

  • Include positive controls (known antiviral proteins) alongside OTUD6B manipulations

• Gene expression modulation strategies:

  • Use CRISPR-Cas9 for OTUD6B knockout (as demonstrated in OTU knockout library screening)

  • Employ siRNA-mediated knockdown (validated in 293T, HT1080, HeLa, and Hep2 cell lines)

  • Implement exogenous expression with HA-tagged OTUD6B (dose-dependent inhibition of viral replication was observed)

  • Include OTUD6B-C57S catalytic mutant as negative control to demonstrate deubiquitinase activity dependence

• Downstream pathway analysis:

  • Monitor type I IFN production using:

    • Luciferase reporter assays for IFN-β promoter activity

    • IFN-stimulatory response element (ISRE) activity measurements

    • qRT-PCR for IFN-β and ISG mRNA levels

    • ELISA for secreted IFN-β protein

  • Assess IRF3 activation status through:

    • Phosphorylation detection

    • Nuclear translocation assays

    • DNA binding capacity

• In vivo validation approaches:

  • Consider mouse models with human OTUD6B overexpression, which showed enhanced resistance to RNA virus infection, reduced viral load, and decreased morbidity

  • Measure viral titers, IFN levels, and inflammatory responses in relevant tissues

What methodological approaches best detect OTUD6B-IRF3 interaction and functional relationship?

The interaction between OTUD6B and IRF3 is a critical aspect of OTUD6B's role in antiviral immunity. To investigate this relationship:

• Protein-protein interaction assays:

  • Co-immunoprecipitation: Demonstrated to be effective for detecting OTUD6B-IRF3 interaction

  • Proximity ligation assay: For visualizing endogenous protein interactions in situ

  • FRET/BRET approaches: For monitoring dynamic interactions in living cells

  • Yeast two-hybrid screening: For mapping interaction domains

• Deubiquitination analysis:

  • In vitro deubiquitination assay: Overexpressing OTUD6B in 293T cells was shown to reduce IRF3 ubiquitination levels

  • Ubiquitin chain-specific antibodies: To distinguish between different ubiquitin linkage types (K11, K33, K48, K63)

  • Ubiquitin mutants: To confirm linkage specificity

  • Mass spectrometry: For comprehensive ubiquitination site mapping

• IRF3 stability assessment:

  • Cycloheximide (CHX) chase assay: For measuring protein half-life (IRF3-K315R mutation showed increased stability compared to wild-type IRF3)

  • Proteasome inhibitors: To confirm degradation pathway

  • Pulse-chase labeling: For quantitative measurement of protein turnover rates

• Mutational analysis:

  • IRF3 lysine mutants: K315R mutation was identified as a major ubiquitin acceptor residue cleaved by OTUD6B

  • OTUD6B catalytic mutant (C57S): Demonstrates dependence on deubiquitinase activity

  • Domain mapping: For identifying minimal regions required for interaction

How can I investigate the differential roles of OTUD6B isoforms in experimental systems?

OTUD6B exists in multiple isoforms with distinct functions. To investigate isoform-specific roles:

• Isoform identification and expression analysis:

  • Design isoform-specific primers for qRT-PCR quantification

  • Use antibodies that can distinguish between isoforms (if available) or epitope-tag different isoforms

  • Create isoform expression maps across tissues and cell types of interest

• Functional differentiation approaches:

  • Express individual isoforms in knockout backgrounds for rescue experiments

  • Compare isoform 1 (translation repressor) with isoform 2 (translation stimulator)

  • Analyze downstream effects on specific targets:

    • For isoform 2: Monitor CCND1/cyclin D1 translation and MYC/c-Myc protein stability

    • For isoform 1: Examine effects on global protein synthesis and mTORC1 signaling

• Subcellular localization studies:

  • Perform fractionation experiments to determine isoform-specific localization

  • Use fluorescently tagged constructs for live-cell imaging

  • Co-localization studies with known interaction partners

• Isoform-specific interactome analysis:

  • BioID or proximity labeling for identifying isoform-specific interacting proteins

  • Co-IP followed by mass spectrometry to map interaction networks

  • Compare interactome differences between isoforms

What considerations are important when using OTUD6B antibodies to study its role in human disease models?

OTUD6B has been implicated in several disease contexts, including antiviral immunity and intellectual disability syndromes. When studying disease relevance:

• Patient-derived sample considerations:

  • For intellectual disability syndrome studies:

    • Compare OTUD6B expression and function in patient-derived cells versus controls

    • Consider the impact of identified mutations on protein function

  • For viral infection studies:

    • Examine expression levels during infection in relevant primary cells

    • Consider polymorphisms that might affect antiviral function

• Disease-relevant experimental systems:

  • Primary cells vs. cell lines (consider physiological relevance)

  • Organoid models for tissue-specific effects

  • Animal models with human OTUD6B expression (mice overexpressing human OTUD6B showed enhanced antiviral responses)

• Methodological adaptations for disease models:

  • Optimize fixation and permeabilization protocols for patient-derived tissues

  • Consider epitope masking in disease states

  • Validate antibody performance in disease-relevant conditions

  • Account for potential post-translational modifications in disease contexts

• Functional readouts in disease contexts:

  • For antiviral studies: Measure viral load, IFN production, and IRF3 stability

  • For neurological disorders: Examine protein synthesis rates and mTORC1 signaling

  • Consider pathway-specific effects based on known OTUD6B functions

How should I approach experimental design when studying OTUD6B's deubiquitinating activity?

OTUD6B's deubiquitinating (DUB) activity is central to its function. To effectively study this activity:

• Ubiquitin chain linkage specificity analysis:

  • In vitro deubiquitination assays with purified components

  • Use linkage-specific ubiquitin antibodies to distinguish between K11, K33, K48, and K63 chains

  • Research shows OTUD6B hydrolyzes both K11 and K33-linked polyubiquitin chains, but only K33-linked polyubiquitin at Lys315 of IRF3 is responsible for IRF3 proteasome degradation

• Substrate identification approaches:

  • Ubiquitin remnant profiling by mass spectrometry

  • BioID or APEX2 proximity labeling with OTUD6B as bait

  • Candidate approach based on known substrates (IRF3 with focus on Lys315)

• Activity-based probe methodology:

  • Use DUB-specific activity-based probes to assess catalytic activity

  • Compare wild-type OTUD6B with catalytic mutant (C57S)

  • Monitor activity changes during viral infection or other stimuli

• Experimental controls and validation:

  • Include both positive controls (known DUBs) and negative controls (catalytically inactive mutants)

  • Validate findings through multiple approaches (biochemical, cellular, in vivo)

  • Consider temporal dynamics of deubiquitination events, particularly during viral infection where OTUD6B levels peak at 8 hours post-infection

What are common challenges when detecting endogenous OTUD6B and how can they be addressed?

Detecting endogenous OTUD6B can present several challenges. Here are methodological solutions:

• Low expression level issues:

  • Optimize protein extraction methods (consider RIPA vs. NP-40 buffers)

  • Increase protein loading (40-60 μg total protein)

  • Use signal enhancement systems (HRP substrates with extended sensitivity)

  • Consider immunoprecipitation before Western blotting to concentrate the target

  • Choose antibodies validated for endogenous detection

• Background and non-specific binding:

  • Optimize blocking conditions (test BSA vs. milk, TBST vs. PBST)

  • Increase washing stringency and duration

  • Try different antibody dilutions (start with manufacturer recommendation of 1:1000)

  • Consider using monoclonal antibodies for higher specificity

• Cell-type specific considerations:

  • Different cell lines may have varying OTUD6B expression levels

  • Include positive control lysates from cells known to express OTUD6B

  • Consider virus-infected samples where OTUD6B levels increase (peaks at 8 hours post-infection)

• Detection during stimulation conditions:

  • For viral infection studies, collect samples at multiple time points to capture expression peaks

  • Include appropriate stimulation controls

  • Consider the stability of protein under different experimental conditions

How can I differentiate between direct and indirect effects when studying OTUD6B function?

Distinguishing direct from indirect effects is crucial for mechanistic studies. Consider these approaches:

• Enzymatic activity dependence:

  • Compare wild-type OTUD6B with catalytically inactive mutant (C57S)

  • Research demonstrated that when the catalyzing activity site of OTUD6B was mutated, it was no longer able to exert antiviral effects

• Temporal resolution approaches:

  • Perform detailed time-course experiments

  • Use inducible expression systems for acute manipulation

  • Consider rapid protein degradation systems (dTAG, AID) for acute loss-of-function

• Substrate specificity verification:

  • Use purified components for in vitro assays

  • Perform site-directed mutagenesis of potential target sites (such as K315R mutation in IRF3)

  • Employ non-ubiquitinatable substrate mutants as negative controls

• Rescue experiments:

  • Perform genetic complementation with wild-type or mutant constructs

  • Use structured experimental designs:

    1. OTUD6B knockdown (enhances viral replication)

    2. OTUD6B overexpression (inhibits viral replication in a dose-dependent manner)

    3. Catalytic mutant expression (no antiviral effect)

    4. Substrate mutation (e.g., IRF3-K315R showed enhanced stability)

What methodological approaches can address contradictory findings about OTUD6B function?

The literature contains some contradictory findings regarding OTUD6B function, particularly between human and zebrafish orthologs. To address these contradictions:

• Species-specific functional differences:

  • Human OTUD6B positively regulates antiviral responses by stabilizing IRF3 through K33-linked deubiquitination

  • Zebrafish OTUD6B reportedly negatively regulates antiviral responses by suppressing K63-linked ubiquitination of IRF3 and IRF7

  • Methodological approach: Perform comparative studies with species-specific constructs in the same experimental system

• Context-dependent function analysis:

  • Test function across multiple cell types and experimental conditions

  • Investigate signaling pathway differences that might explain contradictory results

  • Consider developmental stage and tissue-specific differences

• Comprehensive ubiquitination profiling:

  • Analyze multiple ubiquitin chain types simultaneously (K11, K33, K48, K63)

  • Identify differential substrate preferences

  • Map ubiquitination sites comprehensively using mass spectrometry

• Standardized reporting and methodological transparency:

  • Document detailed experimental conditions

  • Include all relevant controls

  • Report negative findings alongside positive results

  • Consider independent validation in collaboration with other laboratories

How can OTUD6B antibodies be used to investigate its potential role as a therapeutic target?

Given OTUD6B's role in antiviral immunity, it represents a potential therapeutic target. To investigate this potential:

• Therapeutic potential assessment methods:

  • In vivo models: Mice overexpressing human OTUD6B showed enhanced resistance to RNA virus infection, reduced viral load, and decreased morbidity

  • Target validation: Monitor expression and activity during viral infection across diverse cell types

  • Develop activity-based assays suitable for screening modulators

• Small molecule screening approaches:

  • Develop assays measuring OTUD6B deubiquitinating activity

  • Screen for compounds that enhance OTUD6B stability or activity

  • Use antibodies to monitor OTUD6B levels and localization after compound treatment

• Structure-function relationship studies:

  • Combine antibody-based detection with structural biology approaches

  • Identify critical functional domains as potential drug targets

  • Map interaction surfaces between OTUD6B and IRF3

• Therapeutic efficacy markers:

  • Establish antibody-based assays to monitor OTUD6B-dependent pathways

  • Develop biomarkers for OTUD6B activity (IRF3 stability, IFN production)

  • Monitor broader effects on immune signaling networks

What role does OTUD6B play in the broader ubiquitin signaling network?

Positioning OTUD6B within the broader ubiquitin signaling network requires specialized methodological approaches:

• Ubiquitin interactome analysis:

  • Ubiquitin proteomics to identify global changes upon OTUD6B manipulation

  • Compare OTUD6B with other OTU family members (OTUD4, OTUD6A, OTUD7A also showed antiviral effects)

  • Analyze compensatory mechanisms when OTUD6B is absent

• Multi-omics integration strategies:

  • Combine ubiquitin proteomics with transcriptomics and phosphoproteomics

  • Map OTUD6B-dependent signaling networks

  • Correlate OTUD6B activity with global cellular responses

• Pathway cross-talk investigation:

  • Examine intersection with mTORC1 signaling (OTUD6B regulates protein synthesis downstream of mTORC1)

  • Study relationship with proteasome assembly and function

  • Investigate connections between antiviral signaling and other cellular processes

• Temporal dynamics analysis:

  • Monitor ubiquitin signaling changes during viral infection time course

  • Correlate with OTUD6B expression patterns

  • Use live-cell reporters to track dynamic changes in ubiquitination